Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines made from a peptide may help the body build an effective immune response
to kill tumor cells. Colony-stimulating factors, such as GM-CSF, increase the number of white
blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy
after surgery may kill any tumor cells that remain after surgery.
PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients
with newly diagnosed glioblastoma multiforme.
Phase:
Phase 2
Details
Lead Sponsor:
John Sampson
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)